> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-16/
- Published: 2020-04-12T12:00:00.000Z
- Updated: 2026-09-14T16:10:57.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138361

**Menarini-Silicon Biosystems** has completed its agreement to purchase all the assets and relevant business related to the CellSearch Circulating Tumor Cell System from **Janssen Diagnostics**. The FDA-cleared blood test is intended for detecting and enumerating circulating tumor cells (CTCs) to help manage patients with metastatic breast, prostate, and colorectal cancers.

**Sartorius** has acquired **MKS Instruments AB**, a leading specialist in data analytics software for modeling and optimizing biopharmaceutical development and manufacturing processes. Sartorius purchased the company for $72.5 million.

**Sucampo Pharmaceuticals** has acquired for $200 million privately-held [**Vtesse**](http://www.biospace.com/company%5Fprofile.aspx?CompanyId=1013841&ref=fdaweb.com). The transaction gives Sucampo the rights to VTS-270, which is currently in a pivotal study evaluating its effectiveness in treating Niemann-Pick Disease Type C1.

**Syneron** has agreed to be acquired by private equity fund **Apax Partners** for about $397 million. Syneron, and its Candela brand, produce aesthetic medical equipment including body contouring, hair removal and wrinkle reduction devices.